Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) FCF Margin (2020 - 2025)

Historic FCF Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 8.22%.

  • GeneDx Holdings' FCF Margin rose 150000.0% to 8.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.89%, marking a year-over-year increase of 264000.0%. This contributed to the annual value of 11.13% for FY2024, which is 804000.0% up from last year.
  • Per GeneDx Holdings' latest filing, its FCF Margin stood at 8.22% for Q3 2025, which was up 150000.0% from 7.84% recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' FCF Margin ranged from a high of 8.22% in Q3 2025 and a low of 239.34% during Q2 2022
  • Over the past 5 years, GeneDx Holdings' median FCF Margin value was 70.29% (recorded in 2021), while the average stood at 74.32%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -1786500bps in 2022, then soared by 1260300bps in 2023.
  • GeneDx Holdings' FCF Margin (Quarter) stood at 94.5% in 2021, then dropped by -13bps to 106.48% in 2022, then surged by 47bps to 56.14% in 2023, then skyrocketed by 89bps to 6.34% in 2024, then surged by 230bps to 8.22% in 2025.
  • Its last three reported values are 8.22% in Q3 2025, 7.84% for Q2 2025, and 4.65% during Q1 2025.